Identification of staphylococcal lipoteichoic acid-binding proteins in human serum by high-resolution LTQ-Orbitrap mass spectrometry

Molecular Immunology

Volumn 50, Issue 3, 2012, Pages 177-183

  Jang, Kyoung Soon ^a,c   Baik, Jung Eun ^a   Kang, Seok Seong ^a   Jeon, Jun Ho ^a   Choi, Seulggie ^a   Yang, Yung Hun ^b   Kim, Byung Gee ^a   Yun, Cheol Heui ^a   Han, Seung Hyun ^a  

^a Seoul National University   (South Korea)

^b Konkuk University   (South Korea)

^c California Institute of Technology   (United States)

Author keywords

Lipoteichoic acid; LTA binding protein; LTQ Orbitrap mass spectrometry; Staphylococcus aureus

Indexed keywords

BACTERIAL PROTEIN; HRG PROTEIN; LIPOTEICHOIC ACID BINDING PROTEIN; NANOBEAD; REGULATOR PROTEIN; SEPHAROSE; UNCLASSIFIED DRUG; VIRULENCE FACTOR;

ACCURACY; ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; COMPLEMENT SYSTEM; CONJUGATION; HUMAN; LTQ ORBITRAP MASS SPECTROMETRY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN IMMOBILIZATION; SCREENING; SERUM; STAPHYLOCOCCUS AUREUS; TANDEM MASS SPECTROMETRY;

CARRIER PROTEINS; HUMANS; LIPOPOLYSACCHARIDES; MASS SPECTROMETRY; STAPHYLOCOCCUS; TEICHOIC ACIDS;

BACTERIA (MICROORGANISMS); POSIBACTERIA; STAPHYLOCOCCUS AUREUS;

EID: 84857368791     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2011.11.012     Document Type: Article

References (36)

1. Alves-Filho J.C., Freitas A., Souto F.O., Spiller F., Paula-Neto H., Silva J.S., Gazzinelli R.T., Teixeira M.M., Ferreira S.H., Cunha F.Q. Regulation of chemokine receptor by Toll-like receptor 2 is critical to neutrophil migration and resistance to polymicrobial sepsis. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:4018-4023.
2. Bjornson A.B., Altemeier W.A., Bjornson H.S. Complement, opsonins, and the immune response to bacterial infection in burned patients. Ann. Surg. 1980, 191:323-329.
3. Bublitz M., Polle L., Holland C., Heinz D.W., Nimtz M., Schubert W.D. Structural basis for autoinhibition and activation of Auto, a virulence-associated peptidoglycan hydrolase of Listeria monocytogenes. Mol. Microbiol. 2009, 71:1509-1522.
4. Fischer W. Physiology of lipoteichoic acids in bacteria. Adv. Microb. Physiol. 1988, 29:233-302.
5. Froon A.H., Dentener M.A., Greve J.W., Ramsay G., Buurman W.A. Lipopolysaccharide toxicity-regulating proteins in bacteremia. J. Infect. Dis. 1995, 171:1250-1257.
6. Gao J.J., Xue Q., Zuvanich E.G., Haghi K.R., Morrison D.C. Commercial preparations of lipoteichoic acid contain endotoxin that contributes to activation of mouse macrophages in vitro. Infect. Immun. 2001, 69:751-757.
7. Ginsburg I. The role of bacteriolysis in the pathophysiology of inflammation, infection and post-infectious sequelae. APMIS 2002, 110:753-770.
8. Ginsburg I. Role of lipoteichoic acid in infection and inflammation. Lancet Infect. Dis. 2002, 2:171-179.
9. Gorgani N.N., Altin J.G., Parish C.R. Histidine-rich glycoprotein regulates the binding of monomeric IgG and immune complexes to monocytes. Int. Immunol. 1999, 11:1275-1282.
10. Han S.H., Kim J.H., Martin M., Michalek S.M., Nahm M.H. Pneumococcal lipoteichoic acid (LTA) is not as potent as staphylococcal LTA in stimulating Toll-like receptor 2. Infect. Immun. 2003, 71:5541-5548.
11. Hayashi J., Masaka T., Ishikawa I. Increased levels of soluble CD14 in sera of periodontitis patients. Infect. Immun. 1999, 67:417-420.
12. Hortin G.L. The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome. Clin. Chem. 2006, 52:1223-1237.
13. Huang L., Harvie G., Feitelson J.S., Gramatikoff K., Herold D.A., Allen D.L., Amunngama R., Hagler R.A., Pisano M.R., Zhang W.W., Fang X. Immunoaffinity separation of plasma proteins by IgY microbeads: meeting the needs of proteomic sample preparation and analysis. Proteomics 2005, 5:3314-3328.
14. Jang K.S., Baik J.E., Han S.H., Chung D.K., Kim B.G. Multi-spectrometric analyses of lipoteichoic acids isolated from Lactobacillus plantarum. Biochem. Biophys. Res. Commun. 2011, 407:823-830.
15. Jiao Y.L., Wu M.P. Apolipoprotein A-I diminishes acute lung injury and sepsis in mice induced by lipoteichoic acid. Cytokine 2008, 43:83-87.
16. 2+ chelation. J. Biol. Chem. 2004, 279:30114-30122.
17. Kaiser E., Colescott R.L., Bossinger C.D., Cook P.I. Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. Anal. Biochem. 1970, 34:595-598.
18. Kessler R.E., van de Rijn I. Effects of penicillin on group A streptococci: loss of viability appears to precede stimulation of release of lipoteichoic acid. Antimicrob. Agents Chemother. 1981, 19:39-43.
19. LeBouder E., Rey-Nores J.E., Rushmere N.K., Grigorov M., Lawn S.D., Affolter M., Griffin G.E., Ferrara P., Schiffrin E.J., Morgan B.P., Labeta M.O. Soluble forms of Toll-like receptor (TLR)2 capable of modulating TLR2 signaling are present in human plasma and breast milk. J. Immunol. 2003, 171:6680-6689.
20. Long E.M., Millen B., Kubes P., Robbins S.M. Lipoteichoic acid induces unique inflammatory responses when compared to other toll-like receptor 2 ligands. PLoS ONE 2009, 4:e5601.
21. Loos M., Clas F., Fischer W. Interaction of purified lipoteichoic acid with the classical complement pathway. Infect. Immun. 1986, 53:595-599.
22. Lynch N.J., Roscher S., Hartung T., Morath S., Matsushita M., Maennel D.N., Kuraya M., Fujita T., Schwaeble W.J. L-ficolin specifically binds to lipoteichoic acid, a cell wall constituent of Gram-positive bacteria, and activates the lectin pathway of complement. J. Immunol. 2004, 172:1198-1202.
23. Mold C. Role of complement in host defense against bacterial infection. Microbes Infect. 1999, 1:633-638.
24. Morath S., Geyer A., Spreitzer I., Hermann C., Hartung T. Structural decomposition and heterogeneity of commercial lipoteichoic acid preparations. Infect. Immun. 2002, 70:938-944.
25. Morath S., von Aulock S., Hartung T. Structure/function relationships of lipoteichoic acids. J. Endotoxin Res. 2005, 11:348-356.
26. Myc A., Buck J., Gonin J., Reynolds B., Hammerling U., Emanuel D. The level of lipopolysaccharide-binding protein is significantly increased in plasma in patients with the systemic inflammatory response syndrome. Clin. Diagn. Lab. Immunol. 1997, 4:113-116.
27. Peterson M.M., Mack J.L., Hall P.R., Alsup A.A., Alexander S.M., Sully E.K., Sawires Y.S., Cheung A.L., Otto M., Gresham H.D. Apolipoprotein B is an innate barrier against invasive Staphylococcus aureus infection. Cell Host Microbe 2008, 4:555-566.
28. Polotsky V.Y., Fischer W., Ezekowitz R.A., Joiner K.A. Interactions of human mannose-binding protein with lipoteichoic acids. Infect. Immun. 1996, 64:380-383.
29. Ryu Y.H., Baik J.E., Yang J.S., Kang S.S., Im J., Yun C.H., Kim D.W., Lee K., Chung D.K., Ju H.R., Han S.H. Differential immunostimulatory effects of Gram-positive bacteria due to their lipoteichoic acids. Int. Immunopharmacol. 2009, 9:127-133.
30. Saigo K., Yoshida A., Ryo R., Yamaguchi N., Leung L.L. Histidine-rich glycoprotein as a negative acute phase reactant. Am. J. Hematol. 1990, 34:149-150.
31. Sallenbach S., Thiel S., Aebi C., Otth M., Bigler S., Jensenius J.C., Schlapbach L.J., Ammann R.A. Serum concentrations of lectin-pathway components in healthy neonates, children and adults: mannan-binding lectin (MBL), M-, L-, and H-ficolin, and MBL-associated serine protease-2 (MASP-2). Pediatr. Allergy Immunol. 1997, 22:424-430.
32. Schroder N.W., Morath S., Alexander C., Hamann L., Hartung T., Zahringer U., Gobel U.B., Weber J.R., Schumann R.R. Lipoteichoic acid (LTA) of Streptococcus pneumoniae and Staphylococcus aureus activates immune cells via Toll-like receptor (TLR)-2, lipopolysaccharide-binding protein (LBP), and CD14, whereas TLR-4 and MD-2 are not involved. J. Biol. Chem. 2003, 278:15587-15594.
33. Schwartzkopff F., Brandt E., Petersen F., Flad H.D., Bock L., Ludwig A. The CXC chemokine NAP-2 mediates differential heterologous desensitization of neutrophil effector functions elicited by platelet-activating factor. J. Interferon Cytokine Res. 2002, 22:257-267.
34. Sriskandan S., Cohen J. Gram-positive sepsis. Mechanisms and differences from gram-negative sepsis. Infect. Dis. Clin. North Am. 1999, 13:397-412.
35. Van Oosten M., Rensen P.C., Van Amersfoort E.S., Van Eck M., Van Dam A.M., Breve J.J., Vogel T., Panet A., Van Berkel T.J., Kuiper J. Apolipoprotein E protects against bacterial lipopolysaccharide-induced lethality. A new therapeutic approach to treat gram-negative sepsis. J. Biol. Chem. 2001, 276:8820-8824.
36. Wicken A.J., Knox K.W. Lipoteichoic acids: a new class of bacterial antigen. Science 1975, 187:1161-1167.